Cl.[NH:2]1[CH2:7][CH2:6][CH:5]([C:8]2[S:9][CH:10]=[C:11]([C:13]3[CH2:17][CH:16]([C:18]4[CH:25]=[CH:24][CH:23]=[CH:22][C:19]=4[CH:20]=[O:21])[O:15][N:14]=3)[N:12]=2)[CH2:4][CH2:3]1.[Cl:26][C:27]1[CH:32]=[CH:31][C:30]([CH3:33])=[C:29]([N:34]=[C:35]=[O:36])[CH:28]=1.O>ClCCl.C(N(C(C)C)CC)(C)C.N12CCCN=C1CCCCC2>[Cl:26][C:27]1[CH:32]=[CH:31][C:30]([CH3:33])=[C:29]([NH:34][C:35]([N:2]2[CH2:3][CH2:4][CH:5]([C:8]3[S:9][CH:10]=[C:11]([C:13]4[CH2:17][CH:16]([C:18]5[CH:25]=[CH:24][CH:23]=[CH:22][C:19]=5[CH:20]=[O:21])[O:15][N:14]=4)[N:12]=3)[CH2:6][CH2:7]2)=[O:36])[CH:28]=1To a suspension of 2-{3-[2-(piperidin-4-yl)-1,3-thiazol-4-yl]-4,5-dihydro-1,2-oxazol-5-yl}benzaldehyde hydrochloride (1.43 g) in dichloromethane (30 ml) and diisopropylethylamine (0.73 ml) were added, at room temperature, 4-chloro-2-isocyanato-1-methylbenzene (700 mg) and one drop of 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU). The mixture was stirred at room temperature overnight, and water was then added. The aqueous phase was removed and extracted with ethyl acetate. The combined organic phases were dried over sodium sulphate and concentrated under reduced pressure. The residue was purified by chromatography. This gave N-(5-chloro-2-methylphenyl)-4-{4-[5-(2-formylphenyl)-4,5-dihydro-1,2-oxazol-3-yl]-1,3-thiazol-2-yl}piperidine-1-carboxamide (1.23 g).